USD 166.53 Billion Global Central Nervous System Treatment Market During 2021-2028 | Fortune Business Insights

Posted on Aug 12 2022 4:54 AM

"Central Nervous System Treatment Market Development Strategy, Key Players, Competitive Landscape, Dynamics, competitive share analysis, CAGR, Size, Industry Share"

The global central nervous system treatment market size is anticipated to reach USD 166.53 billion by 2028 and exhibit a CAGR 0f 9.4% during the forecast period. The increasing geriatric population and the associated neurological disorders are likely to fuel the market growth in the coming years. Fortune Business InsightsTM has presented this information in its report titled “Central Nervous System Treatment Market, 2021-2028”.

The central nervous system treatment market size stood at USD 81.67 billion in 2020 and is estimated to reach USD 89.02 billion in 2021.

The prospective product launches to treat neurological disorders are expected to boost the market growth during the forecast period. The new product launches are likely to augment treatment access in developing nations, favoring the market growth.

Get Sample PDF Brochure: 

https://www.fortunebusinessinsights.com/enquiry/sample/central-nervous-system-treatment-market-103973

Rising Prevalence of Neurological Disorders & Launch of New Products to Propel Market Growth

The increasing prevalence of neurological disorders, including Parkinson’s Alzheimer’s, multiple sclerosis, and others, coupled with the expanding geriatric population, is anticipated to boost the global central nervous system treatment market growth. The Alzheimer’s Association estimates approximately 14 million cases by 2050. This is anticipated to boost the market growth significantly. Additionally, the launch of new prospective products and pipeline drugs is expected to create lucrative growth opportunities for the market. The new product launches are likely to augment the access to treatment in developing nations, thereby fueling the market growth.

Key Players Devise Ingenious Strategies to Capture Growth

The market is fairly consolidated and comprises key players emphasizing strategic distribution agreements and a robust pipeline to retain strong market positions. The market comprises Pfizer Inc., Johnson and Johnson Services Inc., Otsuka Holdings, Novartis AG, and others amongst the top market players. The key players focus on new product launches, partnerships, acquisitions, mergers, and others to improve their market positions. For instance, Biogen announced a deal in January 2020 to acquire a phase 1 stage modulator of circadian rhythm, i.e., PF-05251749. The product is being developed to treat neurological symptoms related to disorders including Alzheimer’s and Parkinson’s disease.

Speak To Our Analyst: 

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/central-nervous-system-treatment-market-103973

Drivers & Restraints

Rising Prevalence of Neurological Disorders to Propel Market Growth

The increasing prevalence of neurological disorders, including Parkinson’s Alzheimer’s, multiple sclerosis, and others, coupled with the expanding geriatric population, is anticipated to boost the global central nervous system treatment market growth. The Alzheimer’s Association estimates approximately 14 million cases by 2050. This is anticipated to boost the market growth significantly.

The launch of new prospective products and pipeline drugs is expected to create lucrative growth opportunities for the market. The new product launches are likely to augment the access to treatment in developing nations, thereby fueling the market growth.

Also, the increasing trend of partnerships, mergers, and acquisitions by key players is projected to bolster the market’s growth during the forecast period.

However, a strict regulatory framework and time-consuming approval process may hinder market growth.

Regional Insights

North America to Gain Ample Growth due to the Strong Presence of Major Market Players

North America is projected to gain the largest global central nervous system treatment market share. The higher access to this treatment and the strong presence of major market players is anticipated to boost the region's market growth. Additionally, government agencies, including the U.S. FDA, to manage central nervous system treatment regulatory guidelines are expected to complement the market’s growth.

Europe is likely to attain the second-largest market share due to appreciative reimbursement policies and wide access to treatment via public healthcare providers in the U.K., such as the National Health Service (NHS).

Asia Pacific is anticipated to witness stellar growth due to the rising geriatric population, growing prevalence of neurological disorders, and improving healthcare infrastructure.

The Middle East & Africa, and Latin America are likely to exhibit sluggish growth due to weaker product penetration and the lack of product approvals.

Key Players in the Global Market are:

  • Biogen (Massachusetts, U.S.)
  • Pfizer Inc. (New York, U.S.)
  • Hoffman-La Roche Ltd. (Switzerland)
  • Novartis AG (Basel, Switzerland)
  • Johnson & Johnson Services, Inc. (New Jersey, U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (Paris, France)
  • Otsuka Holdings (Japan)

Ask for Customization of this Report:

https://www.fortunebusinessinsights.com/enquiry/customization/central-nervous-system-treatment-market-103973

Table Of Contents :

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Key Industry Developments- Mergers, Acquisitions and Partnerships
    • New Product Launches
    • Pipeline Analysis
    • Overview of Regulatory Scenario
    • Impact of COVID-19 on the Market
  • Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2017-2028
    • Immunomodulatory Drugs
    • Interferons
    • Decarboxylase Inhibitors
    • Dopamine Agonists
    • Antidepressants
    • Analgesics
    • Others
    • Neurovascular Diseases
      • Hemorrhagic Stroke
      • Ischemic Stroke
      • Others
    • Neurodegenerative Diseases
      • Alzheimer’s Disease
      • Parkinson’s Disease
      • Multiple Sclerosis
      • Others
    • Mental Health
      • Epilepsy
      • Mood Disorders
      • Anxiety Disorders
      • Others
      • Infectious Diseases
      • Meningitis
      • Encephalitis
      • Others
    • Others
    • Hospital Pharmacy
    • Retail Pharmacy
    • Others
    •  Biologics
    •  Non-biologics
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Drug Class
    • Market Analysis, Insights and Forecast – By Disease Type
    • Market Analysis, Insights and Forecast – By Distribution Channel
    • Market Analysis, Insights and Forecast – By Drug Type
    • Market Analysis, Insights and Forecast – By Region

Toc Continue..

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: [email protected]